Dec 03, 2019 / 03:30PM GMT
David A. Amsellem - Piper Jaffray Companies, Research Division - MD and Senior Research Analyst
Okay. Let's get started. David Amsellem again from the specialty pharma team at Piper Jaffray. Our next fireside chat is Bausch, and with us today is, CEO, Joe Papa. Joe, thanks very much for joining...
Joseph C. Papa - Bausch Health Companies Inc. - CEO & Chairman of the Board
Pleasure to be here.
Questions and Answers:
David A. Amsellem - Piper Jaffray Companies, Research Division - MD and Senior Research AnalystJoining us again this year. And there's a lot to talk about in 25 minutes, so we'll just try to dive right in.
The first question, and it's going to come up so I might as well get it out of the way first is just talk about the balance sheet. What I wanted to ask is specifically what you can and can't do regarding the addition of assets. TRULANCE admittedly was a great add. And certainly, you're acting and looking at bolt-ons. But help us understand your latest thought process here.
Trustpilot
